Juan Manuel Espinosa-Sanchez

Dr. Juan Manuel Espinosa-Sanchez

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2015 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
JEJuan Manuel Espinosa-Sanchez
Juan Manuel Espinosa-Sanchez
Jose Antonio Lopez-EscamezJose Antonio Lopez-Escamez
Jose Antonio Lopez-Escamez
Vestibular migraine (VM) is a common disorder in which genetic, epigenetic and environmental factors probably contribute to its development. The pathophysiology of VM is unknown; nevertheless in the last few years, several studies are contributing to understand the neurophysiological pathways involved in VM. The current hypotheses are mostly based on the knowledge of migraine itself. The evidence of trigeminal innervation of the labyrinth vessels and the localization of vasoactive neuropeptides in the perivascular afferent terminals of these trigeminal fibers support the involvement of the trigemino-vascular system. The neurogenic inflammation triggered by activation of the trigeminal-vestibulocochlear reflex, with the subsequent inner ear plasma protein extravasation and the release of inflammatory mediators, can contribute to a sustained activation and sensitization of the trigeminal primary afferent neurons explaining VM symptoms. The reciprocal connections between brainstem vestibular nuclei and the structures that modulate trigeminal nociceptive inputs (rostral ventromedial medulla, ventrolateral periaqueductal grey, locus coeruleus and nucleus raphe magnus) are critical to understand the pathophysiology of VM. Although cortical spreading depression can affect cortical areas involved in processing vestibular information, functional neuroimaging techniques suggest a dysmodulation in the multimodal sensory integration and processing of vestibular and nociceptive information, resulting from a vestibulo-thalamo-cortical dysfunction, as the pathogenic mechanism underlying VM. The elevated prevalence of VM suggests that multiple functional variants may confer a genetic susceptibility leading to a dysregulation of excitatory-inhibitory balance in brain structures involved in the processing of sensory information, vestibular inputs and pain. The interactions among several functional and structural neural networks could explain the pathogenic mechanisms of VM.

26 February 2017 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
LFLidia Frejo
Lidia Frejo
Eduardo Martin-SanzEduardo Martin-Sanz
Eduardo Martin-Sanz
Roberto TeggiRoberto Teggi
Roberto Teggi
GTGabriel Trinidad-Ruiz
Gabriel Trinidad-Ruiz
ASA. Soto‐Varela
A. Soto‐Varela
T(the Meniere's disease Consortium (MeDiC)
the Meniere's disease Consortium (MeDiC)

22 March 2013 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
TRT. Requena
T. Requena
JEJuan Manuel Espinosa-Sanchez
Juan Manuel Espinosa-Sanchez
SCS. Cabrera
S. Cabrera
GTGabriel Trinidad-Ruiz
Gabriel Trinidad-Ruiz
ASA. Soto‐Varela
A. Soto‐Varela
Jose Antonio Lopez-EscamezJose Antonio Lopez-Escamez
Jose Antonio Lopez-Escamez

24 October 2016 in Frontiers in Neurology
Verified
Journal Article
Open access
LFLidia Frejo
Lidia Frejo
ASAndres Soto-Varela
Andres Soto-Varela
SSSofía Santos-Perez
Sofía Santos-Perez
IAIsmael Aran
Ismael Aran
ÁCÁngel Batuecas Caletrio
Ángel Batuecas Caletrio
Jose Antonio Lopez-EscamezJose Antonio Lopez-Escamez
Jose Antonio Lopez-Escamez
Meniere disease (MD) is a heterogeneous clinical condition characterized by sensorineural hearing loss, episodic vestibular symptoms and tinnitus associated with several comorbidities such as migraine or autoimmune disorders (AD). The frequency of bilateral involvement may range from 5-50% and it depends on the duration of the disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD to identify the best predictors to define clinical subgroups with a potential different etiology to improve the phenotyping of bilateral MD and to develop new treatments. We have defined five clinical variants in bilateral MD. Group 1 is the most frequently found, includes 46% of patients, and is defined by metachronic hearing loss without migraine and without AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, while group 4, that includes 12% of patients, is associated by the presence of migraine in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach can be helpful in selecting patients for genetic and clinical research. However, further studies will be required to improve the phenotyping in these clinical variants for a better understanding of the diverse etiological factors contributing to bilateral MD.

13 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LFLidia Frejo
Lidia Frejo
AGAlvaro Gallego-Martinez
Alvaro Gallego-Martinez
TRTeresa Requena
Teresa Requena
Eduardo Martin-SanzEduardo Martin-Sanz
Eduardo Martin-Sanz
JAJuan Carlos Amor-Dorado
Juan Carlos Amor-Dorado
Jose Antonio Lopez-EscamezJose Antonio Lopez-Escamez
Jose Antonio Lopez-Escamez
Epidemiological studies have found a higher prevalence of allergic symptoms and positive prick tests in patients with Meniere’s disease (MD); however the effect of allergenic extracts in MD has not been established. Thus, this study aims to determine the effect of Aspergillus and Penicillium stimulation in cytokine release and gene expression profile in MD. Patients with MD showed higher basal levels of IL-1β, IL-1RA, IL-6 and TNF-α when compared to healthy controls. We observed that IL-1β levels had a bimodal distribution suggesting two different subgroups of patients, with low and high basal levels of cytokines. Gene expression profile in peripheral blood mononuclear cells (PBMC) showed significant differences in patients with high and low basal levels of IL-1β. We found that both mold extracts triggered a significant release of TNF-α in MD patients, which were not found in controls. Moreover, after mold stimulation, MD patients showed a different gene expression profile in PBMC, according to the basal levels of IL-1β. The results indicate that a subset of MD patients have higher basal levels of proinflammatory cytokines and the exposure to Aspergillus and Penicillium extracts may trigger additional TNF-α release and contribute to exacerbate inflammation.

4 June 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MFMarisa Flook
Marisa Flook
LFLidia Frejo
Lidia Frejo
AGAlvaro Gallego-Martinez
Alvaro Gallego-Martinez
Eduardo Martin-SanzEduardo Martin-Sanz
Eduardo Martin-Sanz
MRMarcos Rossi-Izquierdo
Marcos Rossi-Izquierdo
Jose Antonio Lopez-EscamezJose Antonio Lopez-Escamez
Jose Antonio Lopez-Escamez
Vestibular Migraine (VM) and Meniere's Disease (MD) are episodic vestibular syndromes defined by a set of associated symptoms such as tinnitus, hearing loss or migraine features during the attacks. Both conditions may show symptom overlap and there is no biological marker to distinguish them. Two subgroups of MD patients have been reported, according to their IL-1β profile. Therefore, considering the clinical similarity between VM and MD, we aimed to investigate the cytokine profile of MD and VM as a means to distinguish these patients. We have also carried out gene expression microarrays and measured the levels of 14 cytokines and 11 chemokines in 129 MD patients, 82 VM patients, and 66 healthy controls. Gene expression profile in peripheral blood mononuclear cells (PBMC) showed significant differences in MD patients with high and low basal levels of IL- 1β and VM patients. MD patients with high basal levels of IL- 1β (MDH) had overall higher levels of cytokines/chemokines when compared to the other subsets. CCL4 levels were significantly different between MDH, MD with low basal levels of IL- 1β (MDL), VM and controls. Logistic regression identified IL- 1β, CCL3, CCL22, and CXCL1 levels as capable of differentiating VM patients from MD patients (area under the curve = 0.995), suggesting a high diagnostic value in patients with symptoms overlap.